FDA approves heart protection label change for Repatha
US regulators have approved Amgen’s Repatha as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularisations in adults with cardiovascular disease.
Read More
Tag: evolocumab
Amgen’s Repatha clears blocked arteries, shows study
Amgen has presented clinical data indicating that its PCSK9 inhibitor Repatha could help to reverse heart disease by removing atherosclerotic plaques, showing for the first time that the effect of this class of drugs may go further than reducing cholesterol alone.
Read More
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
